Bone Biologics Corp (BBLG) USD0.001

- Add to watchlist
- This stock can be held in a




Business summary
Bone Biologics Corporation is a medical device company focused on developing and marketing orthobiologic products. The Company is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.
Contact details
Important dates
General stock information
- Short code:
- BBLG
- ISIN:
- US0980703039
- Market cap:
- $17.60 million
- Shares in issue:
- 10.35 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.